ArticlePloS one2025
Global, regional, and national burden of hypertensive intracerebral hemorrhage, 1990 to 2021 and projections to 2050: Results from the Global Burden of Disease Study 2021.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHypertensive intracerebral hemorrhage (HICH) is characterized by high morbidity, mortality, disability, and recurrence. According to the current study, there have been no targeted studies exploring the epidemiology and trends of HICH since the Global Burden of Disease (GBD) study report in 2021. The aim of this study was to assess deaths and disability-adjusted life years (DALYs) of patients with HICH globally from 1990 to 2021, with projections to 2050.
methodsWe analyzed age-standardized death rates (ASDR) and age-standardized DALYs for HICH across various countries, geographic regions, age groups, sexes, and the sociodemographic index (SDI) using data from the 2021 GBD study. In addition, we used a Bayesian age-period-cohort (BAPC) model to project the burden of HICH from 2021 to 2050.
resultsIn 2021, the ASDR for HICH was 22.641 per 100,000 people, reflecting a 31.418% decrease from 1990. Similarly, the age-standardized DALYs rate was 521.085 per 100,000 people, marking a 32.163% reduction since 1990. Country and regional patterns showed stark contrasts: Nauru and Mozambique had the highest ASDRs and age-standardized DALY rates, while Switzerland and Canada reported the lowest. Regionally, Central Africa, South Africa, Central Asia, East Asia, and Southeast Asia had the highest rates, whereas the Americas, Europe, and Oceania had the lowest. Age and gender trends indicated global peaks in the ASDRs (90-94 age group) and age-standardized DALY rates (85-89 age group), with men having higher rates across all age groups. Additionally, both ASDRs and age-standardized DALY rates were negatively associated with SDI levels. Projections from 2021 to 2050 suggest a continued overall decline in global ASDRs and age-standardized DALYs rates for HICH.
conclusionFrom 1990 to 2021, and projected from 2021 to 2050, the global ASDR and age-standardized DALYs rate for HICH have shown an overall decline. However, significant disparities persist between countries and regions, with less developed areas facing a disproportionately higher burden. In these regions, the early implementation of targeted prevention and treatment strategies, alongside continuous improvements in healthcare resources and services, is crucial to mitigating the global burden of HICH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.